Hepatitis B and C seroprevalence in cancer patients: A case control study Kanserli hastalarda hepatit B ve C sikliǧi: Vaka kontrol çalişmasi

Utkan G., AZAP A., Muallaoǧlu S., Tokluoǧlu S., Durnali A. G., Arslan Ü. Y., ...Daha Fazla

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.16, sa.3, ss.103-107, 2006 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 3
  • Basım Tarihi: 2006
  • Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.103-107
  • Anahtar Kelimeler: Hepatitis carrier state, Patient with cancer
  • Ankara Üniversitesi Adresli: Evet

Özet

During the diagnosis and treatment, patients with cancer may either become hepatitis carrier due to one or more reasons, or subject to the risk of hepatitis reactivation as a result of immunosuppressive treatment. This study aims to determine seroprevalence of Hepatitis B (HBV) or Hepatitis C (HCV) in adult patients with cancer, and compare them with patients who were admitted to hospital for non-cancer reasons. This study includes five-hundred patients who have been recently diagnosed with cancer (Group A) and five-hundred patients who were admitted to hospital for other reasons except for cancer (Group B). In Group A, prevalence of HBs Ag, Anti-HBs (AHBs) and Anti-HCV (AHCV) was measured as %4.8, %14, %2.8 respectively while the same rates were measured as %1.2, %42.4, %1.4 in the Group B. When the Group A was compared with the Group B, hepatitis carrier state (HBV or HCV) and HBs carrier state were more common in patients with cancer while a meaningful difference was not seen in regard to HCV. The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.